Family Recall of and Response to Germline Pathologic Variants Found on Paired Tumor-Germline Sequencing in Pediatric Oncology

被引:1
|
作者
Jacobs, Michelle F. [1 ,2 ]
Goldman, Joshua W. [3 ]
Austin, Sarah [2 ]
Koeppe, Erika S. [1 ]
Murad, Andrea M. [2 ]
Koschmann, Carl J. [3 ]
Chinnaiyan, Arul M. [4 ]
Mody, Rajen J. [3 ]
机构
[1] Univ Michigan, Dept Internal Med, Ann Arbor, MI USA
[2] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA
[3] Univ Michigan, Dept Pediat, Ann Arbor, MI USA
[4] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI USA
关键词
CANCER; MUTATIONS; RISK;
D O I
10.1200/PO.23.00539
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSEPaired tumor-germline sequencing can identify somatic variants for targeted therapy and germline pathogenic variants (GPVs) causative of hereditary cancer/tumor predisposition syndromes. It is unknown how patients/families in pediatric oncology use information about an identified GPV. We assessed recall of germline results and actions taken on the basis of findings.METHODSWe completed phone surveys with patients (and/or their parent) with GPVs identified via a single academic medical center's paired tumor-germline sequencing study. Seven hundred forty pediatric (aged 0-25 years) oncology patients were enrolled in this sequencing study between May 2012 and August 2021. Ninety-six participants (13.0%) had at least one GPV identified and were therefore eligible for this survey. The parent/guardian (for patients younger than 18 years or deceased patients) or patients themselves (if 18 years or older) were contacted. Survey topics included germline result recall, experience with genetic counseling, changes to patient's cancer treatment/screening, sharing of results with family members, and lifestyle changes.RESULTSFifty-three surveys (response rate, 55.2%) were completed between October 2021 and June 2022. Thirty-seven (69.8%) respondents correctly recalled the identified GPV. Discussing results with a genetic counselor (P = .0001), having a GPV related to the cancer/tumor diagnosis (P = .002), and non-Hispanic White race/ethnicity (P = .02) were associated with accurate recall. Twenty-five respondents (47.2%) reported a change in the child's cancer treatment and/or screening recommendations, 17 respondents (32.1%) made a lifestyle change on the basis of the results, and 44 respondents (83.0%) shared results with at least one family member.CONCLUSIONWhile most respondents remembered that a GPV was identified in the patient, some did not recall having a GPV found, and others recalled germline findings incorrectly. Future work may determine patient/family preferences for timing/method of result return to optimize patient recall and use of germline results. Pediatric oncology family recall of germline findings varies by age of onset of hereditary cancer risk.
引用
收藏
页数:9
相关论文
共 19 条
  • [1] Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings
    Seifert, Bryce A.
    O'Daniel, Julianne M.
    Amin, Krunal
    Marchuk, Daniel S.
    Patel, Nirali M.
    Parker, Joel S.
    Hoyle, Alan P.
    Mose, Lisle E.
    Marron, Andrew
    Hayward, Michele C.
    Bizon, Christopher
    Wilhelmsen, Kirk C.
    Evans, James P.
    Earp, H. Shelton, III
    Sharpless, Norman E.
    Hayes, D. Neil
    Berg, Jonathan S.
    CLINICAL CANCER RESEARCH, 2016, 22 (16) : 4087 - 4094
  • [2] Looking beyond year 1 in the molecular era of pediatric brain tumor diagnosis: confirmatory testing of germline variants found on tumor sequencing
    Greene, Brittany L.
    Stasi, Shannon M.
    Ting, Michelle A.
    Waligorski, Natalie
    Cole, Bonnie L.
    Lockwood, Christina M.
    Paulson, Vera A.
    Buchan, Jillian G.
    Lee, Amy
    Ojemann, Jeffrey G.
    Ellenbogen, Richard G.
    Stevens, Jeffrey
    Leary, Sarah E. S.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [3] Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
    Schrader, Kasmintan A.
    Cheng, Donavan T.
    Joseph, Vijai
    Prasad, Meera
    Walsh, Michael
    Zehir, Ahmet
    Ni, Ai
    Thomas, Tinu
    Benayed, Ryma
    Ashraf, Asad
    Lincoln, Annie
    Arcila, Maria
    Stadler, Zsofia
    Solit, David
    Hyman, David M.
    Zhang, Liying
    Klimstra, David
    Ladanyi, Marc
    Offit, Kenneth
    Berger, Michael
    Robson, Mark
    JAMA ONCOLOGY, 2016, 2 (01) : 104 - 111
  • [4] Identifying germline pathogenic variants in breast cancer using tumor sequencing
    Cruellas, Mara
    Papakonstantinou, Andri
    Lopez-Fernandez, Adria
    Castillo, Ester
    Matito, Judit
    Gomez, Marina
    Rezqallah, Alejandra
    Vega, Sharela
    Navarro, Victor
    Torres, Maite
    Moles-Fernandez, Alejandro
    Saura, Cristina
    Vivancos, Ana
    Balmana, Judith
    Oliveira, Mafalda
    BREAST, 2025, 81
  • [5] Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children's Oncology Group
    Martin-Giacalone, Bailey A.
    Richard, Melissa A.
    Scheurer, Michael E.
    Khan, Javed
    Sok, Pagna
    Shetty, Priya B.
    Chanock, Stephen J.
    Li, Shengchao Alfred
    Yeager, Meredith
    Marquez-Do, Deborah A.
    Barkauskas, Donald A.
    Hall, David
    McEvoy, Matthew T.
    Brown, Austin L.
    Sabo, Aniko
    Scheet, Paul
    Huff, Chad D.
    Skapek, Stephen X.
    Hawkins, Douglas S.
    Venkatramani, Rajkumar
    Mirabello, Lisa
    Lupo, Philip J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (06): : 733 - 741
  • [6] Parent Quality of Life After Disclosure of Pediatric Oncology Germline Sequencing Results
    Sharp, Katianne M. Howard
    Li, Chen
    Lu, Zhaohua
    Clark, Mary Egan
    Jurbergs, Niki
    Ouma, Annastasia
    Harrison, Lynn
    Gerhardt, Elsie
    Taylor, Leslie
    Hamilton, Kayla V.
    McGee, Rose B.
    Nuccio, Regina
    Hines-Dowell, Stacy
    Gattuso, Jami S.
    Pritchard, Michelle
    Mandrell, Belinda N.
    Tercyak, Kenneth P.
    Nichols, Kim E.
    Johnson, Liza-Marie
    JCO PRECISION ONCOLOGY, 2023, 7
  • [7] Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer
    Gimeno-Valiente, F.
    Martin-Arana, J.
    Tebar-Martinez, R.
    Gambardella, V.
    Martinez-Ciarpaglini, C.
    Garcia-Mico, B.
    Martinez-Castedo, B.
    Palomar, B.
    Garcia-Bartolome, M.
    Segui, V.
    Huerta, M.
    Moro-Valdezate, D.
    Pla-Marti, V.
    Perez-Santiago, L.
    Rosello, S.
    Roda, D.
    Cervantes, A.
    Tarazona, N.
    ESMO OPEN, 2023, 8 (06)
  • [8] A Clinical Approach to Detecting Germline Pathogenic Variants From Tumor-Only Sequencing
    Ceyhan-Birsoy, Ozge
    Misyura, Maksym
    Mandelker, Diana
    JNCI CANCER SPECTRUM, 2020, 4 (03)
  • [9] Germline Cancer Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group
    Li, He
    Sisoudiya, Saumya D.
    Martin-Giacalone, Bailey A.
    Khayat, Michael M.
    Dugan-Perez, Shannon
    Marquez-Do, Deborah A.
    Scheurer, Michael E.
    Muzny, Donna
    Boerwinkle, Eric
    Gibbs, Richard A.
    Chi, Yueh-Yun
    Barkauskas, Donald A.
    Lo, Tammy
    Hall, David
    Stewart, Douglas R.
    Schiffman, Joshua D.
    Skapek, Stephen X.
    Hawkins, Douglas S.
    Plon, Sharon E.
    Sabo, Aniko
    Lupo, Philip J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (07): : 875 - 883
  • [10] Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalence
    Luo, Minjie
    Wong, Derek
    Zelley, Kristin
    Wu, Jinhua
    Schubert, Jeffery
    Denenberg, Elizabeth H.
    Fanning, Elizabeth A.
    Chen, Jiani
    Gallo, Daniel
    Golenberg, Netta
    Patel, Maha
    Conlin, Laura K.
    Maxwell, Kara N.
    Wertheim, Gerald B.
    Surrey, Lea F.
    Zhong, Yiming
    Brodeur, Garrett M.
    MacFarland, Suzanne P.
    Li, Marilyn M.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (08): : 1356 - 1365